Sutro Biopharma Inc

STRO

24.430USD

-0.480-1.93%

Close 03/27, 16:00（ET）Quotes delayed by 15 min

Sutro Biopharma Inc's Score

Industry at a Glance

Industry Ranking

109 / 391

Overall Ranking

224 / 4542

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Sutro Biopharma Inc Highlights

StrengthsRisks

Sutro Biopharma, Inc. is an oncology company engaged in developing site-specific and novel-format antibody drug conjugates (ADCs), enabled by its proprietary integrated cell-free protein synthesis platform, XpressCF, and its site-specific conjugation platform, XpressCF+. It designs and develops therapeutics using the relevant and potent modalities, including ADCs, bispecific ADCs, immunostimulatory ADCs, and dual conjugate ADCs. Enabled through its XpressCF and XpressCF+ platforms, it has entered multi-target, product-focused collaborations with pharmaceutical and biotechnology companies in the field of oncology, with its ongoing relationships that include licensing to Ipsen, on an exclusive basis, the right to research, develop, manufacture and commercialize STRO-003. STRO-003 is developed for the treatment of solid tumors. Its XpressCF and XpressCF platforms supports Vaxcyte, focused on discovery and development of vaccines for the treatment and prophylaxis of infectious disease.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 102.48M.

Fairly Valued

The company’s latest PE is -1.09, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 5.69M shares, decreasing 34.45% quarter-over-quarter.

Held by Ken Fisher

Star Investor Ken Fisher holds 35.30K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.66.

Analyst Rating

Based on 10 analysts

Buy

Current Rating

29.000

Target Price

+16.42%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current financial score of Sutro Biopharma Inc is 5.81, ranking 315 out of 391 in the Biotechnology & Medical Research industry. Its financial status is weak, and its operating efficiency is low. Its latest quarterly revenue reached 11.65M, representing a year-over-year decrease of 21.35%, while its net profit experienced a year-over-year decrease of 35.45%.

Score

Industry at a Glance

Previous score

5.81

Change

0



Financials

5.03

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.20

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

3.78

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

5.96

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.08

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

The current valuation score of Sutro Biopharma Inc is 7.07, ranking 175 out of 391 in the Biotechnology & Medical Research industry. Its current P/E ratio is -1.09, which is -83.51% below the recent high of -0.18 and -231.07% above the recent low of -3.60.

Score

Industry at a Glance

Previous score

7.07

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 109/391

Relevant data have not been disclosed by the company yet.

The current earnings forecast score of Sutro Biopharma Inc is 7.20, ranking 309 out of 391 in the Biotechnology & Medical Research industry. The average price target is 30.00, with a high of 100.00 and a low of 8.00.

Score

Industry at a Glance

Previous score

7.60

Change

-0.4

Support & Resistance

Relevant data have not been disclosed by the company yet.

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current price momentum score of Sutro Biopharma Inc is 9.45, ranking 8 out of 391 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 27.76 and the support level at 19.87, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

9.58

Change

-0.13

Support & Resistance

Relevant data have not been disclosed by the company yet.

Institutional Confidence

Currency: USD Updated: 2026-03-27

The current institutional shareholding score of Sutro Biopharma Inc is 5.00, ranking 136 out of 391 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 66.76%, representing a quarter-over-quarter increase of 8.00%. The largest institutional shareholder is The Vanguard, holding a total of 375.79K shares, representing 2.29% of shares outstanding, with 56.12% decrease in holdings.

Score

Industry at a Glance

Previous score

5.00

Change

0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Affinity Asset Advisors LLC

658.38K

+774.66%

Kynam Capital Management LP

508.81K

--

Millennium Management LLC

452.44K

-4.39%

The Vanguard Group, Inc.

Star Investors

368.30K

-10.50%

Acadian Asset Management LLC

338.93K

+11.41%

Velan Capital Investment Management LP

312.00K

+1.96%

Merck & Co Inc

272.35K

--

Vestal Point Capital, LP

260.00K

--



1

2



The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Sutro Biopharma Inc is 1.04, ranking 345 out of 391 in the Biotechnology & Medical Research industry. The company's beta value is 1.34. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.

Sutro Biopharma Inc

STRO

6.45 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Alkermes Plc

ALKS

8.42 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Madrigal Pharmaceuticals Inc

MDGL

8.27 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

BioCryst Pharmaceuticals Inc

BCRX

8.27 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Day One Biopharmaceuticals Inc

DAWN

8.26 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

IQVIA Holdings Inc

IQV

8.21 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment